Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb 25, 2020	Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020 PRINCETON, N.J. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times Square on Wednesday, February 26, 2020 ....	PDF Version
Toggle SummaryFeb 4, 2016	Agile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by Underwriters PRINCETON, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that the underwriters of its previously announced...	Agile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by Underwriters 18 KB
Toggle SummaryFeb 11, 2019	Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® Company now focused on completing plan to resubmit NDA in first half of 2019. PRINCETON, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced topline results from a comparative wear study testing the...	Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane® 43.4 KB
Toggle SummaryOct 9, 2018	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA PRINCETON, N.J. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has received a response from FDA’s Office of New Drugs (“OND”) concerning the Company’s formal dispute resolution request. The Company had appealed...	Agile Therapeutics, Inc. Completes Formal Dispute Resolution Process with the FDA 36.3 KB
Toggle SummaryFeb 10, 2020	Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive...	PDF Version
Toggle SummaryDec 13, 2018	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® Expects to Announce Results of Meeting After Receipt of Final Minutes from FDA PRINCETON, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018 , it met with the U.S....	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® 34.7 KB
Toggle SummaryOct 24, 2018	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch,...	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) 34.3 KB
Toggle SummaryJun 7, 2018	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been...	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance 26.1 KB
Toggle SummaryJan 10, 2019	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance Discussions with FDA on Design of Comparative Wear Study of Twirla ® and Xulane ® Completed Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019 PRINCETON, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company,...	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance 38 KB
Toggle SummaryMay 18, 2018	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete...	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy 16.9 KB